tirzepatide being discontinued Zepbound (Tirzepatide) for Weight Loss Compounded Tirzepatide (GLP-1/GIP)

Interestingly, when patients started with a lower dose of 2 mg instead of 4 mg, the intensity of these side effects was reduced

The interplay between obesity, weight loss, anti-obesity medication, and suicidal ideation is complex

The safety profile of these medications remains under active surveillance

The role of Tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials

About the review This review aims to simultaneously promote GLP-1 RA research and enhance users' understanding by synthesizing evidence from recent landmark trials, thereby providing a comprehensive picture of the potential of these drugs as more than just metabolic modulators